See more : Jiangxi Changyun Co., Ltd. (600561.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Calliditas Therapeutics AB (publ) (CALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calliditas Therapeutics AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- i-Control Holdings Limited (1402.HK) Income Statement Analysis – Financial Results
- Zodiac Clothing Company Limited (ZODIACLOTH.BO) Income Statement Analysis – Financial Results
- Onde S.A. (OND.WA) Income Statement Analysis – Financial Results
- inTerra Resources Corp (ITRX) Income Statement Analysis – Financial Results
- EQV Ventures Acquisition Corp. (EQV) Income Statement Analysis – Financial Results
Calliditas Therapeutics AB (publ) (CALT)
About Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.21B | 802.88M | 229.35M | 874.00K | 184.83M | 0.00 | 0.00 | 497.00K | 478.00K |
| Cost of Revenue | 77.06M | 15.20M | 0.00 | 0.00 | 0.00 | 51.00K | 51.00K | 56.52M | 51.39M |
| Gross Profit | 1.13B | 787.68M | 229.35M | 874.00K | 184.83M | -51.00K | -51.00K | -56.02M | -50.91M |
| Gross Profit Ratio | 93.62% | 98.11% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | -11,271.63% | -10,650.84% |
| Research & Development | 499.54M | 414.75M | 357.49M | 241.37M | 149.83M | 99.26M | 384.00K | 40.28M | 36.89M |
| General & Administrative | 332.99M | 259.47M | 210.63M | 102.76M | 62.88M | 133.15M | 84.60M | 56.41M | 51.28M |
| Selling & Marketing | 727.74M | 515.19M | 179.60M | 38.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.01B | 774.66M | 390.23M | 141.72M | 62.88M | 133.15M | 84.60M | 56.41M | 51.28M |
| Other Expenses | 0.00 | 20.21M | 6.09M | 0.00 | 0.00 | 51.00K | 51.00K | 112.00K | 111.00K |
| Operating Expenses | 1.51B | 1.21B | 753.80M | 383.10M | 212.71M | 133.20M | 84.65M | 56.52M | 51.39M |
| Cost & Expenses | 1.59B | 1.22B | 753.80M | 383.10M | 212.71M | 133.20M | 84.65M | 56.52M | 51.39M |
| Interest Income | 29.10M | 50.20M | 102.00K | 547.00K | 926.00K | 6.00K | 0.00 | 2.00K | 0.00 |
| Interest Expense | 73.20M | 12.53M | 7.11M | 393.00K | 325.00K | 8.00K | 2.24M | 1.01M | 9.00K |
| Depreciation & Amortization | 16.59M | 12.91M | 34.43M | 2.82M | 1.82M | 51.00K | 51.00K | 112.00K | 111.00K |
| EBITDA | -367.80M | -388.82M | -483.94M | -379.40M | -25.13M | -133.14M | -84.60M | -56.40M | -51.28M |
| EBITDA Ratio | -30.48% | -52.55% | -228.67% | -43,346.80% | -13.60% | 0.00% | 0.00% | -11,348.69% | -10,727.62% |
| Operating Income | -384.40M | -421.94M | -524.46M | -379.72M | -28.02M | -132.48M | -84.51M | -56.02M | -50.91M |
| Operating Income Ratio | -31.85% | -52.55% | -228.67% | -43,446.22% | -15.16% | 0.00% | 0.00% | -11,271.63% | -10,650.84% |
| Total Other Income/Expenses | -72.62M | 5.39M | 9.47M | -53.93M | -4.48M | 1.15M | -2.29M | -395.00K | 375.00K |
| Income Before Tax | -457.02M | -409.42M | -513.37M | -436.15M | -32.50M | -132.05M | -86.79M | -56.91M | -51.01M |
| Income Before Tax Ratio | -37.87% | -50.99% | -223.84% | -49,902.86% | -17.58% | 0.00% | 0.00% | -11,451.11% | -10,672.38% |
| Income Tax Expense | 9.17M | 2.85M | -3.84M | 360.00K | 77.00K | 441.00K | 2.24M | 1.01M | 9.00K |
| Net Income | -466.19M | -412.27M | -509.54M | -436.51M | -32.58M | -132.05M | -86.79M | -56.91M | -51.01M |
| Net Income Ratio | -38.63% | -51.35% | -222.17% | -49,944.05% | -17.63% | 0.00% | 0.00% | -11,451.11% | -10,672.38% |
| EPS | -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -5.09 | -5.81 | -1.71 | -1.54 |
| EPS Diluted | -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -5.09 | -5.81 | -1.71 | -1.54 |
| Weighted Avg Shares Out | 53.67M | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 33.23M | 33.23M |
| Weighted Avg Shares Out (Dil) | 53.67M | 53.02M | 50.83M | 44.87M | 36.94M | 25.95M | 14.93M | 33.23M | 33.23M |
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
STOCKHOLM , Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm.
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
STOCKHOLM , Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg.
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
STOCKHOLM , Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (Nasdaq: CALT) ("Calliditas" or the...
Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript
Calliditas Therapeutics AB (publ) (NASDAQ:CALT ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Renée Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - President, North America Fredrik Johansson - CFO Conference Call Participants...
Calliditas Interim Report January to June 2024
STOCKHOLM , Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK...
Number of shares and votes in Calliditas Therapeutics
STOCKHOLM , July 31, 2024 /PRNewswire/ -- During July, the number of shares and votes in Calliditas Therapeutics AB (publ) has changed due to the exercise of warrants under the company's long-term incentive program issued in 2020, ESOP 2020 and Board...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:...
STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALT
NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, July 27, 2024 / GlobeNewswire/-- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS...
STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT
NEW YORK , July 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus...
Source: https://incomestatements.info
Category: Stock Reports